Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg™ (pegfilgrastim-unne).

Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg™ (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.

"We are pleased to collaborate with Valorum to expand access to affordable treatment options for patients undergoing chemotherapy. This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the U.S. biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines," said Spiro Gavaris, President - U.S. Generics, Lupin.

"We are excited to launch Armlupeg™ (pegfilgrastim-unne) in the U.S. Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise," said Par S. Hyare, CEO of Valorum. "Crucially, we also look forward to providing another option for healthcare providers and patients, increasing access to this important treatment in oncology supportive care."

Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

Shares of Lupin Limited was last trading in BSE at Rs. 2097.65 as compared to the previous close of Rs. 2091.95. The total number of shares traded during the day was 16290 in over 1379 trades.

The stock hit an intraday high of Rs. 2104.80 and intraday low of 2083.90. The net turnover during the day was Rs. 34179180.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals LicensingAgreement Biosimilar Armlupeg USA